The purpose of the Administration Core is to support the translational research objectives of our SPORE in Thyroid Cancer by serving as the organizational hub, optimizing collaboration annong SPORE investigators within and outside MSKCC.
The specific aims ofthe Administrative Core are 1) Provide coordination for all educational and scientific activities ofthe SPORE and 2) Provide centralized administrative support of day- to-day activities to all the components of the SPORE: research projects, cores, and developmental programs. The core will perform the following centralized duties: ? Scientific Review Coordination: Organize the scientific review of ongoing SPORE research projects, cores, and pilot projects as well as the annual solicitation of new pilot projects ? Collaboration: Foster collaborative research within our SPORE as well as with other SPOREs and the wider scientific community ? Financial Management: Serve as the centralized SPORE budgetary coordinator and financial manager ? Editorial Services: Provide editorial services for manuscript publication and grants coordination ? Grants Administration: Serve as administrative liaison to the National Cancer Institute, ensuring the timely submission of all required reports and compliance with institutional and federal regulations. The Administrative Core is led by James Fagin, MD, the SPORE Project Director/Principal Investigator, who will oversee all SPORE activities. Steven Larson, MD will serve as the Co-Director on the core and assist Dr. Fagin. The Administrative Core also includes Jeffrey Knauf, PhD, who will coordinate collaborations, educational functions and meetings, and Mr Matthew Skernolis, who will serve as the financial manager, administrator ofthe grant and coordinate communications with the National Cancer Institute and compliance with institutional and federal regulations.

Public Health Relevance

The Administrative Core serves the essential purpose of centralizing and optimizing collaboration between SPORE investigators. In addition it will provide the institutional environment for proper monitoring of scientific progress, administrative compliance and financial management.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Ganly, Ian; Makarov, Vladimir; Deraje, Shyamprasad et al. (2018) Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell 34:256-270.e5
De Martino, Daniela; Yilmaz, Emrullah; Orlacchio, Arturo et al. (2018) PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. Cancer Lett 439:56-65
Marlow, Laura A; Rohl, Stephen D; Miller, James L et al. (2018) Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. J Clin Endocrinol Metab 103:3169-3182
Krishnamoorthy, Gnana P; Davidson, Natalie R; Leach, Steven D et al. (2018) EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC. Cancer Discov :
Untch, Brian R; Dos Anjos, Vanessa; Garcia-Rendueles, Maria E R et al. (2018) Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Res 78:4642-4657
Knauf, Jeffrey A; Luckett, Kathleen A; Chen, Kuen-Yuan et al. (2018) Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. J Clin Invest 128:4086-4097
Xu, Bin; Scognamiglio, Theresa; Cohen, Perry R et al. (2017) Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon. Hum Pathol 65:133-139
Chandra, Dinesh; Selvanesan, Benson Chellakkan; Yuan, Ziqiang et al. (2017) 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect. Oncotarget 8:20729-20740
Sherman, Eric J; Dunn, Lara A; Ho, Alan L et al. (2017) Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer 123:4114-4121
Di Cristofano, Antonio (2017) SGK1: The Dark Side of PI3K Signaling. Curr Top Dev Biol 123:49-71

Showing the most recent 10 out of 53 publications